Consolidated Statement of Changes in Stockholders' Equity (USD $) In Thousands, except Share data, unless otherwise specified	$0.001 Par Value Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Loss [Member]	Noncontrolling Interest in Subsidiary [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2009	$ 31	$ 120,492	$ 0	$ (1,476,000)	$ 2,616	$ 122,152	$ 243,815
Balance (in shares) at Dec. 31, 2009	30,831,360
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock for the Trubion Pharmaceuticals, Inc. acquisition	3	61,200	0	0	0	0	61,203
Issuance of stock for the Trubion Pharmaceuticals, Inc. acquisition (in shares)	3,351,817
Employee equity award plans activity	1	15,997	0	0	0	0	15,998
Employee equity award plans activity (in shares)	828,246
Non-cash development expenses from joint venture	0	0	0	0	5,995	0	5,995
Net loss attributable to noncontrolling interest	0	0	0	0	(4,514)	0	(4,514)
Net income	0	0	0	0	0	51,698	51,698
Foreign currency translations, net of tax	0	0	0	(634,000)	0	0	(634)
Balance at Dec. 31, 2010	35	197,689	0	(2,110,000)	4,097	173,850	373,561
Balance (in shares) at Dec. 31, 2010	35,011,423
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee equity award plans activity	1	22,965	0	0	0	0	22,966
Employee equity award plans activity (in shares)	991,275
Non-cash development expenses from joint venture	0	0	0	0	5,290	0	5,290
Net loss attributable to noncontrolling interest	0	0	0	0	(6,906)	0	(6,906)
Net income	0	0	0	0	0	23,019	23,019
Foreign currency translations, net of tax	0	0	0	(1,203,000)	0	0	(1,203)
Balance at Dec. 31, 2011	36	220,654	0	(3,313,000)	2,481	196,869	416,727
Balance (in shares) at Dec. 31, 2011	36,002,698						36,002,698
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee equity award plans activity	0	10,310		0	0	0	10,310
Employee equity award plans activity (in shares)	269,852
Non-cash development expenses from joint venture	0	0	0	0	3,670	0	3,670
Stock Repurchased During Period, Value			(5,906)				(5,906)
Stock repurchased during period (in shares)			(403,158)
Net loss attributable to noncontrolling interest	0	0	0	0	(5,381)	0	(5,381)
Net income	0	0	0	0	0	23,524	23,524
Foreign currency translations, net of tax	0	0	0	(816,000)	0	0	(816)
Balance at Dec. 31, 2012	$ 36	$ 230,964	$ (5,906)	$ (4,129,000)	$ 770	$ 220,393	$ 442,128
Balance (in shares) at Dec. 31, 2012	36,272,550						35,869,392